Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity
Translational Vision Science & Technology · 2024
DOI: 10.1167/tvst.13.7.19 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Translational Vision Science & Technology, 2024. Verfasst von Brian Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Doheny Eye Institute, University of California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Ranibizumab, Tomography, Optical Coherence, Choroid, Intravitreal Injections. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
Compare choroidal changes in ranibizumab versus panretinal photocoagulation (PRP)-treated eyes with proliferative diabetic retinopathy (PDR).
Methods
DRCR Retina Network Protocol S post hoc analysis evaluated optical coherence tomography change in choroidal thickness (subfoveal and 3mm superior and inferior to the fovea) through five years; choroidal vascularity index (CVI) was assessed at baseline and one year. Mixed linear models for choroidal change included adjustments for the baseline choroidal value and age.
Results
This study included 328 eyes (158 ranibizumab and 170 PRP) from 256 participants (88 ranibizumab and 95 PRP eyes at five years). Mean change in choroidal thickness from baseline to five years at the fovea was -12 µm in ranibizumab versus -8 µm in PRP (difference [95% confidence interval]: -4 [-18 to 10], P = 0.57), superior was -14 µm versus -19 µm (difference: 5 [-8 to 17], P = 0.45) and inferior was -26 µm versus -32 µm [difference: 5 (-9 to 20), P = 0.45]; change at all three points within the ranibizumab group, and the superior and inferior points for PRP, were statistically significant (P < .05). Mean change in CVI at one year was -0.02% in ranibizumab versus -0.95% in PRP (difference: 0.93 [-0.35 to 2.21], P = 0.14).
Conclusions
In patients with PDR, treatment with ranibizumab versus PRP did not result in statistically significant differences in five-year choroidal thickness or one-year CVI change. Both groups had significant decreases in choroidal thickness at five years. Translational Relevance: Ranibizumab treatment for PDR did not statistically significantly affect choroidal thickness or vascularity differently than PRP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Doheny Eye Institute, University of California, Los Angeles, CA, USA.
- Jaeb Center for Health Research, Tampa, FL, USA.
- DRCR Retina Network, Tampa, FL, USA.
- Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
- Beetham Eye Institute, Joslin Diabetes Center, Boston, MA, USA.
Förderung
- NEI NIH HHS
Zitieren
APA
Lee, B., Josic, K., Nittala, M. G., Velaga, S. B., Karamat, A., Srinivas, S., Corvi, F., Singh, G., Sadda, S., Sun, J. K., Ip, M., & DRCR Retina Network (2024). Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.13.7.19
Vancouver
Lee B, Josic K, Nittala MG, Velaga SB, Karamat A, Srinivas S, et al. Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity. Translational Vision Science & Technology. 2024. doi:10.1167/tvst.13.7.19
BibTeX
@article{Lee2024,
author = {Lee, Brian and Josic, Kristin and Nittala, Muneeswar G and Velaga, Swetha B and Karamat, Ayesha and Srinivas, Sowmya and Corvi, Federico and Singh, Gagan and Sadda, Srinivas and Sun, Jennifer K and Ip, Michael and DRCR Retina Network, DRCR Retina Network},
title = {Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity},
journal = {Translational Vision Science & Technology},
year = {2024},
doi = {10.1167/tvst.13.7.19}
}
EUVIMED